Movement disorders News and Research RSS Feed - Movement disorders News and Research

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2015. For the first quarter of 2015, the Company reported a net loss of $1.2 million, or $0.01 loss per share, compared to a net loss of $11.8 million, or $0.17 loss per share, for the same period in 2014. [More]
Parents share arduous, circuitous journey to get referrals for childhood epilepsy surgery

Parents share arduous, circuitous journey to get referrals for childhood epilepsy surgery

Having a child diagnosed with epilepsy can be a frightening and confusing time. Now, parents share their arduous and "circuitous" journey to get referrals for pediatric epilepsy surgery once their child's disease stops responding to anti-seizure medications. The UCLA study sheds light on the difficulties parents face obtaining specialty and sub-specialty care for their children during an already stressful time. [More]
Boston Scientific, Brainlab form strategic collaboration

Boston Scientific, Brainlab form strategic collaboration

Boston Scientific Corporation announces a collaboration with Brainlab AG, a leading software-driven medical technology company that helps improve patient treatment planning and surgical navigation. [More]
Impulse control disorders do not promote cognitive decline in PD

Impulse control disorders do not promote cognitive decline in PD

Impulse control disorders in patients with Parkinson’s disease are not associated with more marked impairment of cognitive function, researchers report. [More]
Early neuropsychiatric symptoms prevalent in PD

Early neuropsychiatric symptoms prevalent in PD

Neuropsychiatric symptoms, but not cognitive impairment, are common in early untreated patients with Parkinson’s disease, suggest findings from the multicentre Parkinson’s Progression Markers Initiative. [More]
New blood test may more accurately identify biomarkers for Parkinson's disease

New blood test may more accurately identify biomarkers for Parkinson's disease

A new blood test may more accurately identify blood signatures, or biomarkers, for Parkinson's disease (PD), according to a new study published in the journal Movement Disorders. [More]
Neurocrine Biosciences, Mitsubishi Tanabe to develop and commercialize NBI-98854 in select Asian markets

Neurocrine Biosciences, Mitsubishi Tanabe to develop and commercialize NBI-98854 in select Asian markets

Neurocrine Biosciences, Inc. today announced that it has entered into an exclusive collaboration and licensing agreement for the development and commercialization of its VMAT2 inhibitor, NBI-98854, in Japan and other select Asian markets with Mitsubishi Tanabe Pharma Corporation. [More]
Northwestern Medicine opens multidisciplinary treatment center for patients battling Huntington's disease

Northwestern Medicine opens multidisciplinary treatment center for patients battling Huntington's disease

Northwestern Medicine recently launched a multidisciplinary center dedicated to the comprehensive treatment of patients battling Huntington's disease. The new center will focus on both patient care and research of the inherited disease that causes the progressive breakdown of nerve cells in the brain. [More]
Study highlights the treatable causes of cerebellar ataxias

Study highlights the treatable causes of cerebellar ataxias

No cures are possible for most patients who suffer debilitating movement disorders called cerebellar ataxias. But in a few of these disorders, patients can be effectively treated with regimens such as prescription drugs, high doses of vitamin E and gluten-free diets, according to a study in the journal Movement Disorders. [More]
UC San Diego Health System's Movement Disorder Center joins NPF Center of Excellence network

UC San Diego Health System's Movement Disorder Center joins NPF Center of Excellence network

The Movement Disorder Center at UC San Diego Health System has been designated the 41st Center of Excellence in the National Parkinson Foundation's global network. This designation is the highest recognition offered by NPF to a Parkinson's specialty clinic. It represents the consensus of leaders in the field that the UC San Diego program is among the world's leading centers for Parkinson's research, outreach and care. [More]
New study finds that statins may not reduce risk for Parkinson's disease

New study finds that statins may not reduce risk for Parkinson's disease

The use of statins may not be associated with lowering risk for Parkinson's disease, according to a new study led by researchers at Penn State College of Medicine and National Institute of Environmental Health Sciences. The findings cast doubts on reports suggesting that the cholesterol-lowering medications may protect against this neurodegenerative brain disorder. [More]
Movement Disorder Center at UC San Diego designated Center of Excellence in NPF's global network

Movement Disorder Center at UC San Diego designated Center of Excellence in NPF's global network

The Movement Disorder Center at UC San Diego Health System has been designated the 41st Center of Excellence in the National Parkinson Foundation's global network. This competitive designation is the highest recognition offered by NPF to a Parkinson's specialty clinic and represents the consensus of leaders in the field that the multidisciplinary clinic at UC San Diego Health System is among the world's leading centers for Parkinson's research, outreach and care. [More]
Movement tracking device can effectively help assess progression of Parkinson's disease

Movement tracking device can effectively help assess progression of Parkinson's disease

A device that measures movement and balance can effectively help assess and track the progression of Parkinson's disease, even when medications are used to reduce Parkinson's symptoms, UT Southwestern Medical Center research found. [More]
Education can help people better understand individuals with facial paralysis

Education can help people better understand individuals with facial paralysis

A little bit of sensitivity training can help people form better first impressions of those with facial paralysis, reducing prejudices against people with a visible but often unrecognizable disability, new research from Oregon State University indicates. [More]
Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter Plc. and Actavis plc today announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia. [More]
FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia

FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia

Neurocrine Biosciences, Inc. announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration (FDA) for the treatment of congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States. [More]
Disturbed gut microbiome linked to Parkinson’s disease

Disturbed gut microbiome linked to Parkinson’s disease

Research suggests that the intestinal microbiome may be altered in patients with Parkinson’s disease, with some alterations being specific to the motor subtype. [More]
Nonmotor symptoms cluster in Parkinson’s disease patients

Nonmotor symptoms cluster in Parkinson’s disease patients

Nonmotor symptoms tend to appear in specific clusters in patients with Parkinson’s disease and often predate the onset of motor symptoms, research shows. [More]
FDA receives Actavis' NDA resubmission for cariprazine

FDA receives Actavis' NDA resubmission for cariprazine

Actavis plc (NYSE: ACT) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Actavis' New Drug Application (NDA) resubmission for its atypical antipsychotic cariprazine, a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors. [More]
Loyola neurologist finds little scientific evidence that brain games improve cognitive function

Loyola neurologist finds little scientific evidence that brain games improve cognitive function

Computerized brain games that are advertised as a way to help boost intelligence and prevent dementia will be popular Christmas gifts this year. [More]
Advertisement
Advertisement